195 related articles for article (PubMed ID: 20689527)
1. After Avandia, some seek split in drug approval and monitoring.
Dolgin E
Nat Med; 2010 Aug; 16(8):831. PubMed ID: 20689527
[No Abstract] [Full Text] [Related]
2. The truth about rosiglitazone (avandia).
Ledbetter C; Laustsen G
Nurse Pract; 2008 Jun; 33(6):10-1. PubMed ID: 18528195
[No Abstract] [Full Text] [Related]
3. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Misbin RI
Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
[No Abstract] [Full Text] [Related]
4. The long Avandia endgame.
Mullard A
Lancet; 2011 Jul; 378(9786):113. PubMed ID: 21748869
[No Abstract] [Full Text] [Related]
5. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
6. Is the FDA on drugs?
Calabresi M; Park A
Time; 2010 Aug; 176(8):24-8. PubMed ID: 20821962
[No Abstract] [Full Text] [Related]
7. Goodbye avandia!
Alzaid AA
Saudi Med J; 2010 Dec; 31(12):1301-2. PubMed ID: 21135990
[No Abstract] [Full Text] [Related]
8. Drug safety. Planned study of Avandia in doubt after FDA review.
Kean S
Science; 2010 Jul; 329(5990):375. PubMed ID: 20651123
[No Abstract] [Full Text] [Related]
9. Diabetes drug safety update: Avandia and your heart.
Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
[No Abstract] [Full Text] [Related]
10. Prepare for the long haul of drug monitoring.
Gliklich R
Nat Med; 2010 Aug; 16(8):848. PubMed ID: 20689542
[No Abstract] [Full Text] [Related]
11. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
12. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
13. The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
Califf RM; Kramer JM
Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):782-6. PubMed ID: 18655016
[No Abstract] [Full Text] [Related]
14. Rosiglitazone: a case of regulatory hubris.
Nissen SE
BMJ; 2013 Dec; 347():f7428. PubMed ID: 24335808
[No Abstract] [Full Text] [Related]
15. Serious liver injury. Leading reason for drug removals, restrictions.
Meadows M
FDA Consum; 2001; 35(3):8-9. PubMed ID: 11458559
[No Abstract] [Full Text] [Related]
16. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
17. Safety in numbers--monitoring risk in approved drugs.
Okie S
N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
[No Abstract] [Full Text] [Related]
18. Avandia outcome may signal change in epidemiologists' sway.
Wadman M
Nat Med; 2010 Jun; 16(6):614. PubMed ID: 20526293
[No Abstract] [Full Text] [Related]
19. The unfinished business of U.S. drug safety regulation.
Evans BJ; Flockhart DA
Food Drug Law J; 2006; 61(1):45-63. PubMed ID: 16838457
[No Abstract] [Full Text] [Related]
20. Assessing the cardiovascular safety of diabetes therapies.
Goldfine AB
N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
[No Abstract] [Full Text] [Related]
[Next] [New Search]
